Literature DB >> 6871252

Modification of sialic acid metabolism of murine erythroleukemia cells by analogs of N-acetylmannosamine.

E L Schwartz, A F Hadfield, A E Brown, A C Sartorelli.   

Abstract

Two analogs of N-acetylmannosamine, 2-acetamido-1,3,4,6-tetra-O-acetyl-2-deoxy-D-mannopyranose (Ac4-NAcMan) and the 2-trifluoroacetamido derivative (AC4F3-NAcMan), were synthesized as potential inhibitors of the formation of sialic acid-containing glycoconjugates and were examined for their ability to modify the incorporation of N-[3H]acetylamannosamine into cellular glycoconjugates of Friend murine erythroleukemia cells. Ac4F3-NAcMan and Ac4-NAcMan inhibited cellular replication in suspension culture at concentrations of 0.02 and 0.08 mM, respectively. The cytotoxicity of Ac4-NAcMan was relatively reversible, whereas that produced by Ac4-F3-NAcMan was not, as judged by measurement of the cloning efficiencies of cells exposed to these agents. The analogs inhibited incorporation of N-[3H]acetylmannosamine into ethanol-soluble and -insoluble materials. Separation of ethanol-soluble metabolites by HPLC demonstrated that Ac4F3-NAcMan caused accumulation of radioactivity from N-[3H]acetylmannosamine in CMP-N-acetylneuraminic acid (CMP-NeuNAc) equal to the decrease in macromolecular-bound 3H caused by this agent. In contrast, similar exposure to Ac4-NAcMan produced a large increase in the amount of radioactivity in ethanol-soluble N-acetylneuraminic acid while decreasing the amount of label from N-[3H]acetylmannosamine in cellular CMP-NeuNAc, suggesting that the analogs differ in their biochemical sites of action. Treatment of cells with either analog increased the amount of neuraminidase-hydrolyzable sialic acid-like material on the cell surface; this appeared to be due to the incorporation of the analogs into cellular glycoconjugates, since incubation of cells with 3H-labeled analogs resulted in the appearance of radioactivity in cellular ethanol-insoluble and neuraminidase-hydrolyzable material. Incubation of cells with Ac4-NAcMan labeled with 14C in the 4-O-acetyl group further demonstrated that incorporation occurred with approx. 50% retention of this substituent. Thus, both the amount and the nature of the surface sialic acid constituents of treated cells were altered, suggesting that these or similar analogs could potentially be used to modify cellular membrane function.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6871252     DOI: 10.1016/0167-4889(83)90051-4

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  11 in total

Review 1.  Metabolic glycoengineering bacteria for therapeutic, recombinant protein, and metabolite production applications.

Authors:  Christopher T Saeui; Esteban Urias; Lingshu Liu; Mohit P Mathew; Kevin J Yarema
Journal:  Glycoconj J       Date:  2015-05-01       Impact factor: 2.916

Review 2.  Metabolic oligosaccharide engineering: implications for selectin-mediated adhesion and leukocyte extravasation.

Authors:  Ruben T Almaraz; Mohit P Mathew; Elaine Tan; Kevin J Yarema
Journal:  Ann Biomed Eng       Date:  2011-10-30       Impact factor: 3.934

3.  Pharmacological, Physiochemical, and Drug-Relevant Biological Properties of Short Chain Fatty Acid Hexosamine Analogues Used in Metabolic Glycoengineering.

Authors:  Christopher T Saeui; Lingshu Liu; Esteban Urias; Justin Morrissette-McAlmon; Rahul Bhattacharya; Kevin J Yarema
Journal:  Mol Pharm       Date:  2017-09-13       Impact factor: 4.939

4.  A preclinical trial of sialic acid metabolites on distal myopathy with rimmed vacuoles/hereditary inclusion body myopathy, a sugar-deficient myopathy: a review.

Authors:  May Christine V Malicdan; Satoru Noguchi; Ichizo Nishino
Journal:  Ther Adv Neurol Disord       Date:  2010-03       Impact factor: 6.570

5.  Metabolic Glycoengineering of Sialic Acid Using N-acyl-modified Mannosamines.

Authors:  Paul R Wratil; Rüdiger Horstkorte
Journal:  J Vis Exp       Date:  2017-11-25       Impact factor: 1.355

6.  A novel approach to decrease sialic acid expression in cells by a C-3-modified N-acetylmannosamine.

Authors:  Paul R Wratil; Stephan Rigol; Barbara Solecka; Guido Kohla; Christoph Kannicht; Werner Reutter; Athanassios Giannis; Long D Nguyen
Journal:  J Biol Chem       Date:  2014-10-02       Impact factor: 5.157

Review 7.  Metabolic glycoengineering: sialic acid and beyond.

Authors:  Jian Du; M Adam Meledeo; Zhiyun Wang; Hargun S Khanna; Venkata D P Paruchuri; Kevin J Yarema
Journal:  Glycobiology       Date:  2009-08-12       Impact factor: 4.313

Review 8.  Targeting the plasma membrane of neoplastic cells through alkylation: a novel approach to cancer chemotherapy.

Authors:  Matthew Trendowski; Thomas P Fondy
Journal:  Invest New Drugs       Date:  2015-06-23       Impact factor: 3.850

9.  Integration of genetic and metabolic features related to sialic acid metabolism distinguishes human breast cell subtypes.

Authors:  Christopher T Saeui; Alison V Nairn; Melina Galizzi; Christopher Douville; Prateek Gowda; Marian Park; Vrinda Dharmarha; Sagar R Shah; Amelia Clarke; Melissa Austin; Kelley W Moremen; Kevin J Yarema
Journal:  PLoS One       Date:  2018-05-30       Impact factor: 3.240

Review 10.  Improving Immunotherapy Through Glycodesign.

Authors:  Matthew J Buettner; Sagar R Shah; Christopher T Saeui; Ryan Ariss; Kevin J Yarema
Journal:  Front Immunol       Date:  2018-11-02       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.